[Mai zuwa wani babi ne na littafin Lori Weintz, Hanyoyin cutarwa: Magunguna a Lokacin Covid-19.]
Abin takaici, injiniyoyin da gwamnati ke goyan bayansu da magunguna (remdesivir, mRNA Shots, da sauransu) ba su yi aiki don magance matsalar rashin lafiyar numfashi ba. Madadin haka, sun ƙara ƙarin hargitsi a saman cutar mania da ta kama duniya.
Jordan Schachtel
Jaridar bincike
Disamba 13, 2023
A cikin hira da Zuckerberg, baya ga ambaton HCQ, Fauci ya ce, "Akwai wani magani mai suna remdesivir, wanda Gileyad ta samar a matsayin maganin rigakafi. Mun gwada shi a cikin cutar Ebola. Bai yi aiki kamar sauran magungunan ba, amma yana can." Yana da gaske, da gaske a can; remdesivir manufacturer Gileyad ta kashe dala miliyan 2.45 don neman Majalisa a cikin kwata na farko na 2020, wanda kuma shine lokacin da Majalisa ta tsara kuma ta zartar da Dokar Taimakon Coronavirus, Taimako da Tsaron Tattalin Arziki (CARES) wanda ya haɗa da kudade don alluran rigakafi da jiyya don amsa cutar.
An Cire Remdesivir daga Gwajin Ebola Saboda Tasirin Guba:
"Bai yi aiki da kyau ba" ya kasance babban rashin fahimta. A lokacin Gwajin maganin Ebola na 2018 Cibiyoyin Kiwon Lafiya na Ƙasa (NIH), remdesivir (sunan alama Veklury) yana daya daga cikin magunguna daban-daban guda hudu da ake amfani da su wajen magance cutar Ebola. Wadanda ke cikin rukunin remdesivir sun sami mafi yawan mace-mace gabaɗaya, tare da adadin mace-mace sama da kashi 50 cikin ɗari a cikin kwanaki 28 na farko. Mahalarta gwajin da suka karɓi remdesivir suma suna da alamun haɓakar hanta da lalacewar koda, wanda ya jagoranci hukumar tsaro ta dakatar da amfani da ita a tsakiyar gwaji.
Magungunan da ke da bayanin martabar remdesivir ba ɗan takara mai kyau ba ne ga yawancin komai. Ba wai kawai ba shi da tasiri kan cutar Ebola; yana da guba. Me yasa Fauci ma zai yi la'akari da shi?
Robert F. Kennedy, Jr ya bayyana dalili ɗaya a cikin littafinsa Real Anthony Fauci (TAFIYA). Yana da alaƙa da fahimta. Dole NIH ta bayyana tana yi wani abu game da annoba a cikin ɗan gajeren lokaci, duk da cewa dogon buri shine rigakafin. RFK, Jr ya ce:
"Optics sun buƙaci NIH ta ba da wasu albarkatu ga magungunan rigakafin ƙwayoyin cuta; masu sukar za su koka idan [Fauci] ya kashe biliyoyin kan alluran rigakafi kuma ba komai kan warkewa ba. duk wani lasisin rigakafi, sake fasalin rigakafin cutar da ke da tasiri ga Covid don rigakafi ko jiyya da wuri… na iya kashe duk shirin rigakafinsa saboda FDA ba za ta iya ba da izinin amfani da gaggawa na jabs ba. Remdesivir, duk da haka, magani ne na IV, wanda ya dace kawai don amfani da marasa lafiya a asibiti a ƙarshen matakan rashin lafiya. Don haka ba zai yi gogayya da alluran rigakafi ba."(TAFIYA p. 64 an ƙara ƙarfafawa)
Cibiyoyin Cibiyoyin Lafiya na Ma'aikatan Lafiya na Ƙasa suna Riba daga Halayen Magunguna:
Gaskiyar cewa kwamitin ba da shawara na FDA, Kwamitin Ba da Shawarar Magunguna da Abubuwan Halittu masu dangantaka (Farashin VRBPAC), wanda ya gana a yau kuma ya kada kuri'a don ba da shawara ga FDA don ba da EUA (don maganin rigakafi na Covid-19) yana da mahimmanci ... domin abin da ya nuna shi ne cewa tsarin da muke da shi a nan Amurka shine, yanke shawara da shawarwarin da hukumomi masu zaman kansu suka yi. a zahiri, ta ƙungiyoyi masu zaman kansu.
Dokta Anthony Fauci
Daraktan NIAID
Disamba 11, 2020
Dokta Fauci ya bayyana cewa an yanke shawarar da ta shafi lafiyar Amurka da amincinta “a waje da fagen siyasa,” amma babu abin da zai wuce gaskiya. Wani dalilin da RFK, Jr. ke bayarwa don sha'awar Fauci na remdesivir shine kuɗi. An ba da izinin ma'aikatan Cibiyoyin Lafiya na Ƙasa (NIH). sanya sunayensu a kan haƙƙin mallaka, kuma ta haka ne riba daga amincewar samfur. Misali, an jera NIH akan takardar izinin Moderna. Nace, Anthony Fauci Adadin gida ya karu yayin bala'in daga dala miliyan 7.5 zuwa dala miliyan 12.6.
Baya ga rikici na sha'awa a NIH, tare da ma'aikata suna samun riba daga samfuran da suka amince da su, babban kaso na kasafin aiki na NIH, wanda ya haɗa da hukumomi irin su Hukumar Kula da Abinci da Magunguna (FDA), shine. kamfanonin harhada magunguna ke bayarwa - kamfanonin da FDA ke tsara samfuransu. A takaice, akwai kudi da za a samu a cikin remdesivir, kuma babu wanda za a samu ta hanyar amfani da magungunan da aka riga aka amince da su waɗanda ba su da takunkumin haƙƙin mallaka, don haka ba su da tsada.
Wani dan jarida mai bincike Sharyl Attkisson ya gano cewa a lokacin da ake bitar maganin, mambobi goma sha daya na Hukumar Kula da Jiyya ta NIH ta Covid-19 sun dangantakar kudi da Gileyad. Binciken mambobin kwamitin a cikin shekarar da ta gabata ya gano dangantaka da yawa tsakanin mambobin kwamitin NIH da kamfanonin magunguna daban-daban. Gileyad, tare da fatan remdesivir ya zama maganin Covid, an annabta remdesivir zai kawo $ 3.5 biliyan a 2020 kadai.
A cikin Afrilu 2020, sanin rashin lafiyar remdesivir da bayanin martaba mai haɗari, NIAID na Fauci ya fara sashin asibiti na kwanaki 29 gwajin remdesivir a kan masu aikin sa kai na Amurka da ke kwance a asibiti. The Bayanin Protocol Takaitacciyar ta bayyana cewa, "An gwada maganin a baya a cikin mutanen da ke da wasu cututtuka," amma ya yi watsi da ambaton rashin nasararsa gaba daya a gwajin Ebola.
Yunƙurin Remdesivir Duk da Rashin Taimako:
Kafin a kammala binciken Fauci na remdesivir, a binciken da aka gudanar a kasar Sin an sake shi wanda yakamata ya kawar da remdesivir daga aiki.
Binciken kasar Sin ya gano cewa remdesivir na cikin jini:
- bai samar da mahimman tasirin asibiti ko rigakafin cutar ba a cikin marasa lafiya na Covid-19 masu tsananin rashin lafiya,
- ba a haɗa shi da bambancin lokaci don inganta asibiti ba,
- ya haifar da mummunan al'amura a cikin kashi 66% na masu karɓar remdesivir
A takaice, marasa lafiya sun kasance mafi muni da shan remdesivir fiye da idan sun karɓi placebo.
RFK, Jr. ya nuna cewa, "Binciken na kasar Sin ya kasance bazuwar, makafi biyu, mai sarrafa wuribo-tsari mai yawa, nazarin nazari na tsara, wanda aka buga a cikin mujallar kimiyya ta farko ta duniya. The Lancet.” “Sabanin haka, binciken NIAID na Dokta Fauci, a wancan lokacin, har yanzu ba a buga shi ba, ba a sake duba ta ba, ba a bayyana cikakkun bayanai ba. Ya yi amfani da wuribo mai datti kuma ya sami sauye-sauye na ƙa'idar tsaka-tsaki, "wanda bai dace ba a cikin nazarin asibiti. (Lokacin da binciken NIAID ya kasa nuna raguwar cututtuka ko mace-mace, an canza manufar ƙarshen zuwa rage zaman asibiti.)
A datti placebo, wanda kuma aka sani da "spiked," ko "phony" placebo, yana nufin amfani a cikin gwajin magani na "kwatanta mai aiki" maimakon wuribo mai tsabta kamar allurar saline. A wannan yanayin, an ba marasa lafiya da ke hannun magani remdesivir. An ba marasa lafiya a hannun "placebo" remdesivir wanda ya ƙunshi nau'in sinadaran, amma a cikin yanayin da ba a kunna ba. Kamar yadda RFK, Jr. ya bayyana. NIAID na Dokta Fauci ya haɓaka amfani da “spiked” placebos sama da shekaru 40 don “ɓoye munanan illolin magunguna masu guba waɗanda suke neman izini.” (TRAF shafi na 65)
Mai zuwa akwai ginshiƙi daga sashin Makamai da Tsangwama na binciken yana nuna cewa binciken NIH ya yi amfani da wuribo mai datti. Kamar yadda aka nuna a hagu, 200 MG na Remdesivir, tare da wasu sinadarai marasa aiki, an yi amfani da su azaman Placebo Comparator, kuma an yi amfani da 200 MG na Remdesivir azaman maganin gwaji. Hankali zai nuna cewa ƙayyadaddun sakamakon sabon magani, wanda ba a yarda da shi ba zai fi dacewa ta hanyar sanya shi a gaban wani ainihin placebo, maimakon kishiyar sigar da aka gyara na wannan magani.
Dr. Fauci Ya Zaɓi Remdesivir a matsayin "Ma'aunin Kulawa" a Amurka:
Hukumar NIAID ta kashe sama da haka Dala miliyan 70 a matsayin mai biyan haraji kudi dangane da ci gaban remdesivir don maganin Covid-19. Tambaya ce da ta dace a yi tambaya me yasa har ma aka yi la'akari da remdesivir a cikin 2020. An cire shi daga gwajin cutar Ebola a cikin 2018, saboda haɓakar alamomin hanta da koda da kuma adadin mace-macen mahalarta gwaji sama da kashi 50 cikin ɗari.
Fauci, sanin cewa binciken na kasar Sin yana gab da buga shi, wanda zai iya kawo cikas ga amincewar FDA na remdesivir don kula da Covid-19, ya kashe mummunan labari a wani taron manema labarai na Ofishin Oval a ranar 21 ga Afrilu, 2020 yana ayyana "labari mai dadi." Fauci ya ce gwajin asibiti na NIAID ya nuna cewa remdesivir yana rage zaman asibiti na masu cutar Covid da kusan kwanaki hudu. Ya yi watsi da ambaton gagarumin adadin abubuwan da ba su dace ba a cikin hannayen biyu na binciken, Da kuma cewa Ninki biyu na abubuwan da ake amfani da su na remdesivir fiye da abubuwan placebo dole ne a sake dawo da su asibiti bayan an sallame su, wanda ya haifar da tambayar sakin farko don sa lambobin su yi kyau. Fauci ya ce yana kawo karshen binciken, zai ba da remdesivir ga rukunin placebo, kuma remdesivir zai zama sabon "ma'auni na kulawa" na Amurka ga Covid. (TAFIYA shafi na 66)
Wata mai tsira daga Holocaust Vera Sharav, wacce ta sadaukar da rayuwarta don fallasa cin hanci da rashawa a masana'antar gwaji ta asibiti, ta ce:
Dr. Fauci yana da sha'awar remdesivir. Ya dauki nauyin gwajin asibiti wanda cikakken sakamakonsa bai kasance ƙarƙashin nazarin takwarorinsa ba da ya buƙaci magungunan da ya ɗauka a matsayin abokan hamayya, kamar hydroxychloroquine da ivermectin. Maimakon nuna bayanan gaskiya da sakamako masu gamsarwa, ya yi 'kimiyya' ta fiat. (TAFIYA p. 67)
Mayu 1, 2020 FDA Ta Ba da Tallafin Remdesivir Izin Amfani na Gaggawa:
A ranar 29 ga Afrilu, kwanaki takwas bayan Fauci na sama yayi magana game da taron manema labarai na Ofishin Oval, da Nazarin kasar Sin wanda ya nuna mummunan halayen remdesivir a cikin kashi 66% na masu karɓar gwaji, An buga a cikin Lancet. Ba tare da yanke hukunci ba, NIH ta fitar da wani Sakon labarai yana mai cewa "gwajin asibiti na NIH ya nuna Remdesivir yana hanzarta murmurewa daga ci gaba na Covid-19." Bayan kwana biyu a ranar 1 ga Mayu, 2020 FDA ya mai da remdesivir sabon magani na Covid da aka Izinin Amfani da Gaggawa (EUA).
Kudin Remdesivir Kasa da Dala 6 don Kera shi, amma Kudinsa $3k don Jiyya:
Amincewa da FDA ta remdesivir a matsayin ma'aunin kulawa na Covid-19 yana nufin cewa Medicaid da kamfanonin inshora ba za su iya musun shi bisa doka ba ga marasa lafiya, kuma likitoci da asibitocin da suka kasa amfani da shi za a iya kai karar su don rashin aiki. (TAFIYA, p. 67) Gileyad, wanda ke kera remdesivir a kasa da $6 don hanya na magani, yana cajin kusan $3,000 (dangane da inshora) don magani na kwanaki 5. Sabanin haka, tsarin kwanaki 5 na HCQ yana kashe ƙasa da $20. Ko ta yaya, shugaban Gileyad ya ɗauka cewa wannan ciniki ne:
Yayin da duniya ke ci gaba da jajircewa daga tasirin dan Adam, zamantakewa da tattalin arziki na wannan annoba, mun yi imanin cewa farashin remdesivir da bai kai kima ba shi ne abin da ya dace kuma abin da ke da alhakin yi.
Daniel O'day, Yuni 29, 2020
Shugaban & Shugaba, Kimiyyar Gileyad
Mai kera Remdesivir
Gaskiya ne cewa bincike da ƙira, da farashin masana'antu, duk wani ɓangare ne na haɓaka magunguna, don haka ƙila babban rarrabuwar kawuna a cikin ƙirƙira farashin da farashin kasuwa ya ɗan dace. Amma farashi a gefe, bayanin martabar aminci akan remdesivir da HCQ yana da hankali. Lokacin da remdesivir ya kasance cikakken yarda a cikin Oktoba 2020, FDA ta ce, "Ba a gudanar da gwaje-gwajen hulɗar miyagun ƙwayoyi na Veklury (remdesivir) da sauran magunguna a cikin mutane ba," ma'ana ba a san irin mummunar hulɗar da zai iya yi da wasu kwayoyi ba.
An san Remdesivir yana haifar da matsalolin koda, da haɓaka matakan enzymes na hanta, alamar lalacewar hanta. Ba a gwada Remdesivir don aminci ba a cikin mata masu ciki ko masu shayarwa. A daya bangaren kuma, an shafe kusan shekaru 70 ana amfani da HCQ, kuma ana iya rubutawa yara da manya masu shekaru daban-daban ciki har da mata masu juna biyu da masu shayarwa.
Ana yi wa Remdesivir Laƙabin "Run-Mutuwa-Kusa!"
Duk waɗannan ka'idoji, tsoron tsoro, keɓewa, magunguna masu guba - Na yi tafiya kamar na shiga cikin kisan kai na likita.
Gail Macrae
Nurse a Los Angeles
Nurse Gail Macrae ya yi aiki a Cibiyar Kiwon Lafiya ta Kaiser Permanente Santa Rosa a California yayin bala'in. Kamar yadda kafafen yada labarai sun nace cewa asibitoci sun cika da masu cutar Covid, Macrae ya lura akasin haka. "Ba su taɓa cika majinyata ba," in ji Macrae. A zahiri, daga farkon Covid, tsawon shekarar farko ta cutar, ba wai kawai ya kasance ba asibitin yafi karfin aiki, amma Macrae ta sauye-sauye a matsayin ma'aikaciyar kwangila sau da yawa an soke shi saboda rashin marasa lafiya. Tarin jimlar marasa lafiya a asibitocin gundumar Los Angeles daga Maris 2020 zuwa Maris 2021 ya tabbatar da ƙwarewar Macrae:
Marasa lafiya akan Remdesivir Kwarewa akai-akai Mummunan Mummunan Al'amura:
Baya ga samun damuwa ta hanyar watsa labarai na rashin gaskiya, Macrae kuma ta sami kanta cikin kariyar ka'idojin jiyya na Covid-19. Ita da sauran ma'aikatan jinya za su yi magana a tsakanin su kuma suna tambayar dalilin da ya sa ake gudanar da gwajin gwajin rigakafin cutar ta EUA ga marasa lafiya a cikin cututtukan da ke gaba, lokacin da maganin rigakafi ba zai yi tasiri sosai ba. Ba su ga wani ci gaba a cikin marasa lafiya da ke karɓar remdesivir, kuma a gaskiya ma, da aka gudanar da yawancin marasa lafiya suna shiga cikin gazawar kwayoyin halitta. (A lokacin bala'in, wasu ma'aikatan jinya mai suna remdesivir "Run-mutu-na-kusa.") Macrae ta kawo damuwarta ga masu kulawa kuma aka ce mata, "Wannan yarjejeniya ce. Wannan shi ne kawai abin da muke da shi. Babu wani abu da za mu iya bayarwa."
Hukumar Lafiya ta Duniya ta Ba da Shawarwari Kan Remdesivir don Magance Covid-19:
A cikin Oktoba 2020 Hukumar Lafiya ta Duniya (WHO) shawara akan amfani da remdesivir a cikin marasa lafiya na Covid-19 a asibiti. Hukumar ta WHO, tana mai karawa binciken kasar Sin na Afrilu 2020, ta ce akwai babu shaida cewa Remdesivir yana da tasiri mai kyau akan "mutuwar mace-mace, buƙatar iskar inji, lokaci don inganta asibiti, da sauran sakamako masu mahimmanci na haƙuri." Wannan binciken ya dogara ne akan sakamakon da aka samu a cikin Gwajin Solidarity na WHO wanda ya shafi manya 11,330 a cikin kasashe 30.
Dokta Andre Kalil, tare da Cibiyar Kiwon Lafiya ta Kasa, yayi watsi da gwajin Solidarity na WHO, da'awar "ƙananan ƙirar binciken bincike," kuma ya nuna sakamakon daga gwajin NIH wanda ya nuna remdesivir ya haifar da rage zaman asibiti a cikin manya tare da Covid-19. Dokta Kalil shi ne babban mai bincike a kan shari’ar NIH da yake magana a kai, wato irin fitinar da Fauci ya kare bayan taron manema labarai na fadar White House na Afrilu 2020. Gwajin iri ɗaya wanda ya nuna munanan abubuwan da suka faru a cikin "131 daga cikin marasa lafiya 532 waɗanda suka karɓi remdesivir (24.6%) da kuma a cikin 163 na marasa lafiya 516 waɗanda suka karɓi gyara remdesivir (31.6%)."
Ko da yake bayanan gwaji da kuma ainihin ƙwarewar filin kasance nuna cewa remdesivir bai inganta sakamako ba ga marasa lafiya na Covid, remdesivir an ba da cikakkiyar amincewar FDA a ciki Oktoba 2020. A cikin ba da izini, FDA ta ambaci binciken Fauci na NIH, kuma ta amince da remdesivir don amfani da marasa lafiyar yara masu shekaru 12 zuwa sama, dangane da ƙaramin binciken da masana'antar remdesivir ta Gilead Sciences ta dauki nauyinsa. Fox mai gadin gidan kaji ya zo a hankali.
Arziki daga Remdesivir:
Yayin da HCQ da ivermectin ke lalata ta hanyar FDA, NIH, da kafofin watsa labarai na yau da kullun, Tallafin kudi da gwamnatin tarayya ta bayar don amfani da remdesivir, da sauran ka'idoji na hukuma a cikin asibitin sun kasance masu ban mamaki.
An Labari akan Ƙungiyar Likitocin Amurka da Likitoci sun bayyana, “Dokar CARES yana ba da ƙarfafawa don asibitoci su yi amfani da magungunan da gwamnatin tarayya ta tsara kawai a karkashin kulawar NIH." Ƙarfafa kuɗi don amfani da ƙa'idodin da gwamnatin tarayya ta amince da su sun haɗa da:
- Gwajin “kyauta” da ake buƙata na PCR a cikin Dakin Gaggawa ko lokacin shigar da kowane majiyyaci, tare da kuɗin da gwamnati ta biya zuwa asibiti.
- Ƙara ƙarin biyan kuɗi don kowane tabbataccen bincike na Covid-19.
- Wani kari don shigar da Covid-19 zuwa asibiti.
- Kashi 20 cikin XNUMX na “ƙarfafa” biyan kuɗi daga Medicare akan duk lissafin asibiti don amfani da remdesivir. (girmamawa kara da cewa)
- Wani kuma mafi girma biyan kuɗi ga asibiti idan mai haƙuri na Covid-19 ya sami iska ta inji.
- Ƙarin kuɗi zuwa asibiti idan an jera dalilin mutuwar a matsayin Covid-19, koda mara lafiya bai mutu kai tsaye na Covid-19 ba.
- Binciken Covid-19 kuma yana ba da ƙarin biyan kuɗi ga masu binciken.
Gwamnatin tarayya kuma tayi tayin a Dalar Amurka 10k na jana'izar ga iyalan majinyata wadanda takardar shaidar mutuwar ta ce sun mutu ne daga Covid.
Babban Mai Shari'a Thomas Renz da CMS (Cibiyoyin Sabis na Medicaid) masu ba da labari sun ƙididdige adadin ƙarin biyan kuɗi na akalla $ 100,000 ga kowane majiyyaci. Waɗannan abubuwan ƙarfafawa na kuɗi sun haifar da jiyya waɗanda galibi ba su da fa'ida ga marasa lafiya. Tabbas, allunan asibitocin da suka yi asarar miliyoyi yayin kulle-kullen asibiti - babu mara lafiya da aka yarda sai dai idan kuna da Covid-19 ko ciwon zuciya, don yin magana - sun yi marmarin cika asusunsu.
Afrilu 25, 2022 FDA ta Amince da Remdesivir ga Jarirai da Yara:
Duk da hatsarin profile, da FDA ta amince remdesivir “a wasu yanayi masu haɗari masu haɗari, kamar asibiti, ranar 25 ga Afrilu, 2022. A lokacin FDA kuma ta amince da izinin yin amfani da gaggawa na remdesivir a jarirai.
Patricia Cavazzoni, tsohuwar ma'aikaciyar Pfizer kuma darekta na Cibiyar Nazarin Magunguna da Magunguna ta FDA, ta ce, "Kamar yadda Covid-19 na iya haifar da rashin lafiya mai tsanani a cikin yara, wasu daga cikinsu ba su da zaɓin rigakafin a halin yanzu, ana ci gaba da buƙatar amintattun zaɓuɓɓukan magani na COVID-19 ga wannan yawan."
Wani likita a wani asibitin yara na North Carolina, bayan samun labarin amincewar FDA ya bayyana cewa, "Muna buƙatar ingantattun zaɓuɓɓukan maganin rigakafin ƙwayar cuta, kamar remdesivir, wanda zai iya taimakawa wajen kula da wasu mafi rauni a cikin al'ummarmu: yara."
Wadannan likitocin a fili ba su sani ba, ko dai ta hanyar rashin iyawa ko jahilci mai ma'ana, na daruruwan binciken da ke nuna nasara tare da ƙananan magunguna masu guba.
Covid-19 baya haifar da Mummunan Haɗari ga Yara da Matasa:
Bari mu fito fili. Jarirai, yara, da matasa ba su cikin haɗari saboda cutar Covid-19, wani abu da muka sani da wuri (duba nan da kuma nan). A duk lokacin bala'in, kamuwa da cutar Covid-19 a cikin yara ya kasance mai laushi. Bayanan CDC (ya zuwa 29 ga Nuwamba 2023) sun nuna cewa a cikin shekarun 0-17, a cikin kusan shekaru huɗu na annoba, an sami adadin mutuwar 1,696 da aka danganta ga Covid, wanda ke da kashi 1.29% na duk mace-mace a cikin wannan rukunin a lokacin. A takaice dai, kashi 98.71% na mace-mace a cikin wadanda shekarunsu suka wuce 0-17 sun kasance saboda wasu dalilai.
Amma duk da haka an sami lahani mai yawa ta hanyar rufe fuska, keɓewa daga abokai da dangi, rufe makarantu, rufe wuraren wasan motsa jiki da wuraren shakatawa na skate, soke ayyukan karin karatu da sau ɗaya a cikin al'amuran rayuwa kamar zuwa gida da yawon buɗe ido, da kuma rikicewar rayuwa ta yau da kullun. Hakanan ana iya faɗi ga ƙungiyar 18-29. Covid ya kai kashi 3.04% na duk mace-mace a cikin wannan rukunin shekaru kusan shekaru huɗu na cutar. Yayin da mace-mace ta Covid-19 ba ta da yawa, amma amsa zuwa Covid-19 ya haifar da ingantaccen haɓaka magungun abu, Kamar yadda bakin ciki da damuwa girma, kuma yunkurin kashe kansa kuma kashe kansa ya karu.
Tun farkon barkewar cutar, an san cewa nakasassu da mace-mace sakamakon Covid-19, a cikin mutanen da ke ƙasa da 50, kusan ba tare da togiya sun faru a cikin waɗanda suka kamu da cutar ba. matsalolin kiwon lafiya na asali wanda aka kara Covid.
A cikin nazarin takaddun shaida na mutuwa, Cibiyar Kididdigar Kiwon Lafiya ta Kasa, wacce ta tattara bayanan duk mace-mace a Amurka, ruwaito a cikin Disamba 2020 cewa:
Kashi 6% na mace-mace, Covid-19 shine kawai sanadin da aka ambata. Ga mace-mace tare da yanayi ko sanadi ban da COVID-19, a matsakaita, akwai ƙarin yanayi 2.9 ko sanadin mutuwa. ”
A takaice dai, kawai kashi 6% na mutuwar Covid ne ainihin Covid ya haifar da shi - sauran 94% sun mutu "tare da Covid," tare da ɗimbin sauran yanayin kiwon lafiya. Wannan adadi mai ban mamaki na kashi 6% ya haɗa da duk ƙungiyoyin shekaru, har ma da tsofaffi da marasa ƙarfi.
A lokacin Covid-19, al'umma ta karya kwangilar da ba a rubuta ba don kare tsara mai zuwa. Zaluntar yaranmu da matasanmu a lokacin bala'in Covid-19, don cutar da ba ta da hadari ga matasa, lallai ne a gane shi a matsayin daya daga cikin mafi girman rashin da'a a tarihin Al'ummarmu.
Tsangwamar da Gwamnati ba a taɓa yin irinsa ba a cikin dangantakar Likita/Masu haƙuri:
Tsangwama da gwamnati ke yi a harkar likitanci na daya daga cikin batutuwan da aka tattauna a wani zama na ranar 18 ga Mayu, 2023 na Kwamitin Zabe na Majalisa kan Cutar Coronavirus. Kamar yadda daya daga cikin membobin kwamitin, Rep. Rich McCormick, wanda kwararren likita ne a Jojiya ya fada:
Yayin da [annobar] ta ci gaba, na fahimci cewa gwamnati ita ce babbar matsalar kowa… Sun shiga tsakanin ƙwararru da marasa lafiya. Sun ware iyalai. Ba su bar mutane ma su mutu da mutunci ba, ko da wani zaɓi a cikin lafiyarsu.
Wannan tsangwama a cikin dangantakar likita / haƙuri yana bayyana a cikin ci gaba da amfani da remdesivir, duk da gazawar koda da / ko wasu. mummunan abubuwa a yawancin masu cutar Covid. Hakanan, tallafin kuɗi don ba da iska ga marasa lafiya ya ci gaba, duk da haka Sanannun yawan mace-mace ga wadanda aka samu iska.
tarayya reimbursement don amfani da remdesivir da iskar injina a cikin marasa lafiya na Covid da ke asibiti ya ci gaba har zuwa Satumba na 2023, kodayake ƙarshen dokar gaggawa ta ƙasa ta kasance a ranar 11 ga Mayu, 2023.
Remdesivir, Wanda Aka Sani Don Yin Lalacewa Koda, An Amince Ga Marasa lafiya da Cutar Koda:
Haɗin kalmomin "m gazawar koda" da "remdesivir" sun haifar da siginar rashin daidaituwa na ƙididdiga tare da lokuta 138 da aka lura maimakon 9 da ake tsammani.
An buga nazari Disamba 19, 2020
Clinical Pharmacology & Magunguna
Ana samun ƙarin shaidar cin hanci da rashawa a cikin tsarin amincewar FDA a cikin Yuli 14, 2023 yarda na remdesivir don maganin Covid-19 a cikin masu fama da cutar koda. Dr. Peter McCullough jihohin, "Remdesivir na iya haifar da raunin koda da kuma hanta ... Ayyukan amincewa da FDA ya saba wa tunani kuma za a saka shi cikin jerin jerin ayyukan da za a yi la'akari da rashin kuskure. ”…
Labari sun yi yawa na mutanen da aka yi wa remdesivir da iskar iska, ba tare da ingantaccen izini ba, wani lokacin ma ba tare da son rai ba. Wasu asusun suna ba da umarnin alkalai don ba da izini ga marasa lafiya don gwada IVM da HCQ a asibiti, duk da bayanin martabar aminci da rashin rashin daidaituwa tare da wasu magunguna - ma'ana, ba zai iya cutar da gwadawa ba kuma yana iya taimakawa.
Kararraki Game da Gileyad don Rage Hatsarin Clinical na Remdesivir:
An fara shigar da kararraki daga mutanen da suke jin 'yan uwansu ne kashe, ba ta Covid-19 ba, amma ta remdesivir, gami da a Ƙungiyar kisa-mataki An shigar da shi a California a ranar 26 ga Satumba, 2023. Ƙarar aikin aji ta yi iƙirarin cewa masana'antar remdesivir ta Gilead Sciences "ba ta bayyana da/ko ta bar ainihin abun ciki da yanayin maganin ba." Ɗaya daga cikin lauyoyin da ke bin shari'ar ya ce, "Mummunan magani ne ... za ku iya ganin akwai bambanci sosai a cikin matakan creatinine da matakan jini, karatun koda bayan sun sami remdesivir."
Abin baƙin ciki, gazawar Dokta Fauci don cimma burin lafiyar jama'a yayin bala'in cutar ta Covid ba kurakurai ba ne, amma daidai da tsarin sadaukar da lafiyar jama'a da aminci a kan bagadin ribar magunguna da son kai.
Robert F. Kennedy, Jr.
Shigar, Real Anthony Fauci
Shiga cikin tattaunawar:
An buga ƙarƙashin a Commonirƙirar Commonabi'a Mai Creativeayatarwa 4.0 Licenseasashen Duniya
Don sake bugawa, da fatan za a saita hanyar haɗin yanar gizo zuwa asali Cibiyar Brownstone Labari da Marubuci.
